NYSE:TARO - Taro Pharmaceutical Industries Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$106.18 +0.74 (+0.70 %)
(As of 08/14/2018 04:00 PM ET)
Previous Close$105.44
Today's Range$105.15 - $107.14
52-Week Range$93.01 - $128.46
Volume51,100 shs
Average Volume71,438 shs
Market Capitalization$4.21 billion
P/E Ratio17.10
Dividend YieldN/A
Beta0.5
Taro Pharmaceutical Industries logoTaro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Zrt.

Receive TARO News and Ratings via Email

Sign-up to receive the latest news and ratings for TARO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:TARO
CUSIPN/A
Phone972-4847-5700

Debt

Debt-to-Equity RatioN/A
Current Ratio8.79
Quick Ratio8.12

Price-To-Earnings

Trailing P/E Ratio17.10
Forward P/E Ratio10.98
P/E GrowthN/A

Sales & Book Value

Annual Sales$661.91 million
Price / Sales6.33
Cash Flow$6.6654 per share
Price / Cash15.93
Book Value$56.06 per share
Price / Book1.89

Profitability

EPS (Most Recent Fiscal Year)$6.18
Net Income$211.15 million
Net Margins34.18%
Return on Equity11.82%
Return on Assets10.77%

Miscellaneous

Employees1,413
Outstanding Shares39,430,000
Market Cap$4.21 billion

Taro Pharmaceutical Industries (NYSE:TARO) Frequently Asked Questions

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) released its quarterly earnings data on Thursday, August, 9th. The company reported $1.71 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.33 by $0.62. The company had revenue of $154.62 million for the quarter, compared to the consensus estimate of $179.54 million. Taro Pharmaceutical Industries had a net margin of 34.18% and a return on equity of 11.82%. View Taro Pharmaceutical Industries' Earnings History.

When is Taro Pharmaceutical Industries' next earnings date?

Taro Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Taro Pharmaceutical Industries.

What price target have analysts set for TARO?

1 analysts have issued 1 year price objectives for Taro Pharmaceutical Industries' stock. Their forecasts range from $120.00 to $120.00. On average, they anticipate Taro Pharmaceutical Industries' share price to reach $120.00 in the next twelve months. This suggests a possible upside of 13.0% from the stock's current price. View Analyst Price Targets for Taro Pharmaceutical Industries.

What is the consensus analysts' recommendation for Taro Pharmaceutical Industries?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Taro Pharmaceutical Industries.

Who are some of Taro Pharmaceutical Industries' key competitors?

Who are Taro Pharmaceutical Industries' key executives?

Taro Pharmaceutical Industries' management team includes the folowing people:
  • Mr. Ara Aprahamian, VP of Sales & Marketing (Age 50)
  • Mr. Michael Perfetto, Group VP (Age 57)
  • Mr. Uday V. Baldota, CEO & Director (Age 48)
  • Mr. Mariano Balaguer, CFO, Chief Accounting Officer & VP (Age 45)
  • Mr. Itamar Karsenti, VP & Head of Operations (Age 46)

Has Taro Pharmaceutical Industries been receiving favorable news coverage?

News coverage about TARO stock has been trending positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Taro Pharmaceutical Industries earned a media and rumor sentiment score of 0.26 on Accern's scale. They also gave news stories about the company an impact score of 46.40 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View Recent Headlines for Taro Pharmaceutical Industries.

Who are Taro Pharmaceutical Industries' major shareholders?

Taro Pharmaceutical Industries' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (1.66%), Renaissance Technologies LLC (0.73%), Dimensional Fund Advisors LP (0.66%), Acadian Asset Management LLC (0.60%), Fort L.P. (0.40%) and Alps Advisors Inc. (0.15%).

Which major investors are selling Taro Pharmaceutical Industries stock?

TARO stock was sold by a variety of institutional investors in the last quarter, including Fort L.P., Brandes Investment Partners LP, Canada Pension Plan Investment Board, Alps Advisors Inc., Alps Advisors Inc., BlackRock Inc., First Trust Advisors LP and Aperio Group LLC.

Which major investors are buying Taro Pharmaceutical Industries stock?

TARO stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Robeco Institutional Asset Management B.V., Renaissance Technologies LLC, Boston Partners, Connor Clark & Lunn Investment Management Ltd., FMR LLC, Bank of New York Mellon Corp and Paloma Partners Management Co.

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Taro Pharmaceutical Industries' stock price today?

One share of TARO stock can currently be purchased for approximately $106.18.

How big of a company is Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries has a market capitalization of $4.21 billion and generates $661.91 million in revenue each year. The company earns $211.15 million in net income (profit) each year or $6.18 on an earnings per share basis. Taro Pharmaceutical Industries employs 1,413 workers across the globe.

How can I contact Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries' mailing address is 14 HAKTOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 972-4847-5700 or via email at [email protected]


MarketBeat Community Rating for Taro Pharmaceutical Industries (NYSE TARO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  186 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  320
MarketBeat's community ratings are surveys of what our community members think about Taro Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TARO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TARO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/14/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.